Skip to Main content Skip to Navigation
New interface
Journal articles

How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer

Abstract : Recombinant human TSH (rhTSH) is used in patients who have had surgery for thyroid cancer but are at low risk of recurrence. The rhTSH is used for the preparation of postoperative administration of 3.7 GBq (100 mCi) of radioiodine for thyroid-remnant ablation and for the determination of serum thyroglobulin levels during follow-up. In these two conditions, the efficiencies of levothyroxine withdrawal and rhTSH administration are similar; however, rhTSH can be administered during levothyroxine treatment, and its use avoids the hypothyroid period induced by levothyroxine withdrawal, reduces whole body exposure after radioiodine administration, avoids potential morbidity and maintains a better quality of life compared with hormone withdrawal.
Document type :
Journal articles
Complete list of metadata

https://hal-cnrs.archives-ouvertes.fr/hal-03477039
Contributor : Colette ORANGE Connect in order to contact the contributor
Submitted on : Monday, December 13, 2021 - 11:58:46 AM
Last modification on : Wednesday, November 30, 2022 - 3:32:49 AM

Identifiers

Collections

Citation

M Schlumberger, M Ricard, Gérard de Pouvourville, F Pacini. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3 (9), pp.641-50. ⟨10.1038/ncpendmet0594⟩. ⟨hal-03477039⟩

Share

Metrics

Record views

15